Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disor...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

Bubblebusterguy Jul. 7 at 7:28 PM

$IGC never holds gains.. right back underground tomorrow 🥴👍

0 · Reply

Tom678 Jul. 7 at 7:27 PM

$IGC amazing

0 · Reply

Bulltrader988 Jul. 7 at 7:25 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-announces-equity-analyst-coverage-by-alliance-global-h0t6r7w6qz36.html

0 · Reply

Bulltrader988 Jul. 7 at 7:22 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-announces-coverage-report-by-ascendiant-capital-markets-4oci8nh8c9aa.html

0 · Reply

Bulltrader988 Jul. 7 at 6:57 PM

$IGC 👃👀

0 · Reply

Bulltrader988 Jul. 4 at 7:22 PM

$IGC 👃👀

0 · Reply

Neeky21 Jul. 3 at 4:19 PM

$TLRY $IGC

0 · Reply

Tom678 Jul. 2 at 2:40 PM

$IGC $1 soon

0 · Reply

Bubblebusterguy Jul. 2 at 2:34 PM

$IGC Run it!! I’m not giving you my shares so make the move already!

0 · Reply

IGC Jul. 1 at 2:22 PM

$IGC hosted its Fiscal Year-End 2025 Shareholder Update Call yesterday, covering key milestones from the past year and our outlook for the CALMA Trial, AI platform, and pipeline expansion. Replay available here: https://www.webcaster4.com/Webcast/Page/2938/52547 #IGCPharma, #ShareholderCall, #BiotechNews, #investors, #stakeholders, #businessupdate, #FiscalYearEnd2025

0 · Reply

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 10 days ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 14 days ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 6 weeks ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 4 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 5 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 5 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 6 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 7 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 2, 2024, 8:30 AM EST - 7 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Nov 25, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 14, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 6, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Oct 17, 2024, 8:30 AM EDT - 9 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 3, 2024, 9:00 AM EDT - 9 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Sep 18, 2024, 8:00 AM EDT - 10 months ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 4, 2024, 8:00 AM EDT - 10 months ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 8, 2024, 9:30 PM EDT - 11 months ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

Jul 18, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 9, 2024, 9:10 AM EDT - 1 year ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jun 25, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 10, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

May 28, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 21, 2024, 2:00 PM EDT - 1 year ago

IGC Pharma to Attend BIO International Convention 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 9, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Adds Advisor in Artificial Intelligence

Mar 26, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Mar 20, 2024, 11:00 AM EDT - 1 year ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

Mar 20, 2024, 7:00 AM EDT - 1 year ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Mar 12, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

Feb 23, 2024, 12:01 PM EST - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

Feb 16, 2024, 7:05 PM EST - 1 year ago

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Feb 1, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Jan 23, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

Jan 17, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

Dec 19, 2023, 9:20 AM EST - 1 year ago

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

Bubblebusterguy Jul. 7 at 7:28 PM

$IGC never holds gains.. right back underground tomorrow 🥴👍

0 · Reply

Tom678 Jul. 7 at 7:27 PM

$IGC amazing

0 · Reply

Bulltrader988 Jul. 7 at 7:25 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-announces-equity-analyst-coverage-by-alliance-global-h0t6r7w6qz36.html

0 · Reply

Bulltrader988 Jul. 7 at 7:22 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-announces-coverage-report-by-ascendiant-capital-markets-4oci8nh8c9aa.html

0 · Reply

Bulltrader988 Jul. 7 at 6:57 PM

$IGC 👃👀

0 · Reply

Bulltrader988 Jul. 4 at 7:22 PM

$IGC 👃👀

0 · Reply

Neeky21 Jul. 3 at 4:19 PM

$TLRY $IGC

0 · Reply

Tom678 Jul. 2 at 2:40 PM

$IGC $1 soon

0 · Reply

Bubblebusterguy Jul. 2 at 2:34 PM

$IGC Run it!! I’m not giving you my shares so make the move already!

0 · Reply

IGC Jul. 1 at 2:22 PM

0 · Reply

Bulltrader988 Jul. 1 at 6:05 AM

$IGC 👃👀 https://www.tipranks.com/news/company-announcements/igc-pharma-reports-transformative-year-in-alzheimers-innovation?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Bulltrader988 Jun. 30 at 6:07 PM

$IGC 👃👀 https://www.tipranks.com/news/the-fly/igc-pharma-reports-fy25-eps-9c-vs-22c-last-year-thefly?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Bulltrader988 Jun. 30 at 2:07 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-fiscal-year-2025-financial-and-operational-highlights-a-nytprixf65ep.html

0 · Reply

Tom678 Jun. 28 at 1:45 AM

$IGC

0 · Reply

Bulltrader988 Jun. 27 at 10:10 PM

$IGC beat? 👀👀 https://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm

0 · Reply

RAGC Jun. 27 at 8:24 PM

$IGC news 👇 https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm

0 · Reply

Bulltrader988 Jun. 27 at 2:40 PM

$IGC monday pre market 👃👀 "... will host a conference call and webcast on Monday, June 30, 2025, at 11:00 a.m. Eastern.." https://www.stocktitan.net/news/IGC/igc-pharma-to-host-fiscal-year-end-2025-shareholder-update-call-on-fwjx6gzv2433.html

1 · Reply

Bubblebusterguy Jun. 26 at 10:24 PM

$IGC Gib a penny, take a penny! Dank you come again… India!🤘

0 · Reply

Bulltrader988 Jun. 26 at 10:11 PM

$IGC 👃👀

0 · Reply

Happy_Feet19 Jun. 26 at 10:02 PM

$IGC What are the 3 to 6 month updates that will move this stock price?

0 · Reply

IGC Jun. 24 at 8:34 PM

$IGC We’re proud to announce the expansion of our Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia, with a new site opening at Tekton Research in Yukon, Oklahoma. This strategic addition reflects IGC Pharma’s commitment to addressing regional healthcare disparities and enhancing diversity across our clinical studies. Led by Dr. David McCoy, a board-certified neurologist and native Oklahoman, the Yukon site brings deep expertise in Alzheimer’s research and strengthens our ability to reach underrepresented populations. This milestone also underscores our broader mission: to combine advanced clinical research with AI-powered innovation—to accelerate drug discovery, optimize clinical trials, and improve patient targeting in the fight against neurodegenerative diseases. #IGCPharma #TektonResearch #AlzheimersResearch #AlzheimersDisease #Agitation #IGCAD1 #CALMA #ClinicalTrials #NeurodegenerativeDiseases #Neuroscience #InnovationInCare #PharmaInnovation

0 · Reply

Bulltrader988 Jun. 24 at 7:02 PM

$IGC yesterday 👃👀

0 · Reply

Market Cap	24.11M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-562.99%
Debt to Equity Ratio	0.02

Volume	388,100
Avg Vol	233,282
Day's Range	N/A - N/A
Shares Out	79.69M
Stochastic %K	71%
Beta	1.45
Analysts	Sell
Price Target	$3.88